470 A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59)

• Byoung Chul Cho,
• Jae-Lyun Lee,
• Myoung Ho Jang,
• Hyung Soon Park,
• Byoung Yong Shim,
• Sang Joon Shin,
• Nari Yun,
• Mina Ham,
• Young Jun Koh

Affiliations

Byoung Chul Cho

Yonsei University College of Medicine, Seoul, Republic of Korea

Jae-Lyun Lee

Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea

Myoung Ho Jang

2Academy of Immunology and Microbiology, Institute for Basic Science, Pohang, Republic of Korea

Hyung Soon Park

Division of Medical Oncology, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of)

Byoung Yong Shim

8The Catholic University of Korea, Suwon, Korea, Republic of

Sang Joon Shin

1Yonsei University College of Medicine, Seoul, Korea, Republic of

Nari Yun

4GI Innovation, Inc, Seoul, Kosovo, Republic of

Mina Ham

4GI Innovation, Inc, Seoul, Kosovo, Republic of

Young Jun Koh

4GI Innovation, Inc, Seoul, Kosovo, Republic of